Back to Search Start Over

Development of A Standardized Opsonophagocytosis Killing Assay for Group B Streptococcus and Assessment in an Interlaboratory Study.

Authors :
Leung S
Collett CF
Allen L
Lim S
Maniatis P
Bolcen SJ
Alston B
Patel PY
Kwatra G
Hall T
Thomas S
Taylor S
Le Doare K
Gorringe A
Source :
Vaccines [Vaccines (Basel)] 2023 Nov 09; Vol. 11 (11). Date of Electronic Publication: 2023 Nov 09.
Publication Year :
2023

Abstract

The placental transfer of antibodies that mediate bacterial clearance via phagocytes is likely important for protection against invasive group B Streptococcus (GBS) disease. A robust functional assay is essential to determine the immune correlates of protection and assist vaccine development. Using standard reagents, we developed and optimized an opsonophagocytic killing assay (OPKA) where dilutions of test sera were incubated with bacteria, baby rabbit complement (BRC) and differentiated HL60 cells (dHL60) for 30 min. Following overnight incubation, the surviving bacteria were enumerated and the % bacterial survival was calculated relative to serum-negative controls. A reciprocal 50% killing titer was then assigned. The minimal concentrations of anti-capsular polysaccharide (CPS) IgG required for 50% killing were 1.65-3.70 ng/mL (depending on serotype). Inhibition of killing was observed using sera absorbed with homologous CPS but not heterologous CPS, indicating specificity for anti-CPS IgG. The assay performance was examined in an interlaboratory study using residual sera from CPS-conjugate vaccine trials with international partners in the Group B Streptococcus Assay STandardisatiON (GASTON) Consortium. Strong correlations of reported titers between laboratories were observed: ST-Ia r = 0.88, ST-Ib r = 0.91, ST-II r = 0.91, ST-III r = 0.90 and ST-V r = 0.94. The OPKA is an easily transferable assay with accessible standard reagents and will be a valuable tool to assess GBS-specific antibodies in natural immunity and vaccine studies.

Details

Language :
English
ISSN :
2076-393X
Volume :
11
Issue :
11
Database :
MEDLINE
Journal :
Vaccines
Publication Type :
Academic Journal
Accession number :
38006035
Full Text :
https://doi.org/10.3390/vaccines11111703